InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,533.68
(
-0.56%
)
Post# of 5006
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

sabaidii2

Send PM Follow Ignore
Followers 0
Posts 138
Boards Moderated 0
Alias Born 08/12/2016

sabaidii2

Re: sabaidii2 post# 4499

Thursday, 07/13/2017 11:00:32 PM

Thursday, July 13, 2017 11:00:32 PM

Post# of 5006
4) RXI-109 (dermal scarring reduction) - DOA (Dead On Arrival). No interim test results, such as photos, have been released for cohorts 3&4, as opposed to what was shown for Samcyprone. That is a huge red flag. Don't be surprised to hear "We've decided to initiate a Phase 2B study".
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent PHIO News
More PHIO News
InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news
Only $200 per official company press release!